Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INGLAXA-1: 4D-310 in Fabry Disease
NCT04519749Phase 2Active, not recruiting
- Sponsor
- 4D Molecular Therapeutics
- Start
- Sep 2020
- Primary completion
- Jan 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of 4D-310 in Fabry disease (FD), sponsored by 4D Molecular Therapeutics. Started Sep 2020; status: active, not recruiting.
02
Drugs
4D-310
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT04519749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04519749.